| Activated FGFR2 as a Viable Therapeutic Target in a Subset of Ovarian Cancers |
Jul-2009 |
25 pages |
| Authors:
Pamela Pollack; TRANSLATIONAL GENOMICS RESEARCH INST PHOENIX AZ
|
 | Ovarian cancer is the leading cause of death from gynecologic malignancies in the Western world. Fibroblast growth factor receptor (FGFR) signaling has been implicated to play a role in ovarian tumorigenesis. Given our recent report of activating mutations in FGFR2 in endometrioid endometrial tumors and the similarities in the molecular genetics of ovarian and endometrial cancer, we hypothesized that activating FGFR2 mutations may also occur in a subset of ovarian ... |
|
| Regulatory T Cells and Host Anti-CML Responses |
Jun-2009 |
9 pages |
| Authors:
Wong; K K Jr; CITY OF HOPE BECKMAN RESEARCH INST DUARTE CA
|
| CD4+CD25+FoxP-3+ regulatory T-cells (Tregs) suppress immune responses to 'self' antigens, but also have been shown to suppress host anti-tumor responses in several human malignancies, including breast, gastrointestinal, and ovarian cancer. Identification of CML Tregs as suppressors of host anti-CML responses could have a significant impact upon CML treatment strategies. Methods are currently available to selectively suppress Tregs and subsequently boost host anti-CML responses. We have examined the CD4+CD25+FoxP-3+ regulatory T-cell ... |
|
| Identification and Functional Characterization of Somatic Mutations in Human MicroRNAs and their Responsive Elements in Target Genes in Ovarian Tumor Tissues |
May-2009 |
6 pages |
| Authors:
Hua Zhao; HEALTH RESEARCH INC BUFFALO NY
|
| Epithelial ovarian cancer (EOC) continues to be the leading cause of the death among gynecological malignancies, owing to the lack of preventive strategies, early diagnostic methods or effective therapies. Detailed understanding of molecular changes, such as, somatic mutations, in ovarian cancer holds the promise of greatly contributing to the understanding of ovarian cancer pathogenesis, with obvious implications in development of new biomarkers, prevention strategies and therapy Micro-RNAs (miRNAs) are endogenous ... |
|
| Inhibition of Ovarian Cancer by microRNA-mediated Regulation of Telomerase |
May-2009 |
51 pages |
| Authors:
Brittney-Shea Herbert; INDIANA UNIV INDIANAPOLIS
|
| A hallmark of ovarian cancer is its limitless proliferative potential which is governed in part by elevated levels of human telomerase (hTERT) or telomerase activity. However, how telomerase can be regulated in normal cells, and how this regulation can be lost during cancer progression, is not completely understood. microRNAs (miRNAs) are evolutionarily conserved, small, non-coding, single-stranded, 19-23 nucleotide RNA molecules that are estimated to negatively regulate protein encoding genes including ... |
|
| Ovarian Carcinoma Stem Cells |
May-2009 |
28 pages |
| Authors:
Richard Jones; JOHNS HOPKINS UNIV BALTIMORE MD SCHOOL OF MEDICINE
|
| Ovarian carcinoma is one of the most responsive solid tumors, with the majority of affected women now achieving complete remissions; unfortunately, most of these women eventually relapse and die from the disease. We hypothesized that the initial clinical responses represent therapeutic effectiveness against differentiated cancer cells making up the bulk of the tumor, while the high rate of relapses result from rare, biologically distinct resistant cancer stem cells (CSC). The ... |
|
| Development and Screening of Subtractive RNAi Libraries from Ovarian Cancer Cell Lines |
Apr-2009 |
6 pages |
| Authors:
Alexandre B Dimtchev; GEORGETOWN UNIV WASHINGTON DC
|
| The Specific aims of this proposal are: (1) Construction of two subtractive RNAi libraries targeting mRNA transcripts predominantly present in an (a) advanced ovarian cancer cell line and (b) metastatic ovarian cancer cell line. (2) Screen for genes vitally important for survival and growth. The two malignant cell lines will be transfected with individual clones from the subtractive RNAi libraries and the effect on viability will be monitored. Clones from ... |
|
| Modulators of Response to Tumor Necrosis-Related Apoptosis-Inducing Ligand (TRAIL) Therapy in Ovarian Cancer |
Apr-2009 |
18 pages |
| Authors:
Kian Behbakht; COLORADO UNIV HEALTH SCIENCES CENTER AURORA CO
|
| Ovarian Cancer is the leading cause of death from gynecologic cancers in the developed world. We have previously identified a homeobox gene, Six1, which is overexpressed in ovarian cancers as compared to normal ovarian surface epithelium. Overexpression of Six1 is associated with resistance to Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) based therapies. We have discovered that this resistance in ovarian cancers is likely related to over-expression of the TRAIL ... |
|
| Development of a Multifaceted Ovarian Cancer Therapeutic and Imaging Agent |
Apr-2009 |
7 pages |
| Authors:
Francis S Markland; UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES
|
| Ovarian cancer (OC) is the deadliest of all gynecological cancers, with five year survival rates of 45%. One critical feature of the disease is that two-thirds of the women diagnosed have advanced disease, and the five year survival rate of this group is 30%. This project outlines the development of a recombinant version of a member of a class of proteins known as disintegrins as an innovative imaging and diagnostic ... |
|
| Role of PELP1 in EGFR-ER Signaling Crosstalk in Ovarian Cancer Cells |
Apr-2009 |
48 pages |
| Authors:
Ratna K Vadlamudi; TEXAS UNIV HEALTH SCIENCE CENTER AT SAN ANTONIO
|
| Ovarian cancer is an endocrine-related cancer, but it remains unknown which hormone-regulated mechanisms are critical in ovarian cancer pathogenesis. In this study, we have identified nuclear hormonal receptor coregulator, Proline-, glutamic acid-, and leucine-rich protein-1 (PELP1/MNAR) as a novel proto-oncogene for ovarian cancer and showed that PELP1/MNAR is 2 to 3 fold overexpressed in 60% of ovarian tumors. To examine the significance of PELP1/MNAR in ovarian cancer progression, we have ... |
|
| BRCA1 in Gene-specific Coordination of Transcription and DNA-Damage Response |
14-Mar-2009 |
9 pages |
| Authors:
Jianlong Sun; TEXAS UNIV HEALTH SCIENCE CENTER AT SAN ANTONIO
|
| BRCA1 is a tumor suppressor gene for hereditary breast and ovarian cancers. In collaborating with various binding partners, BRCA1 protein participates in multiple cellular functions. Characterization of these binding proteins of BRCA1 is therefore key to the complete understanding of BRCA1's role in tumor suppression. Cofactor of BRCA1 (COBRA1) is a novel BRCA1-interacting protein and shares several functional commonalities with BRCA1 in regulating expression of genes involved various types of ... |
|
| Identification of Ovarian Cancer Susceptibility Genes Involved in Stromal-Epithelial Interactions |
Feb-2009 |
27 pages |
| Authors:
Georgia Chenevix-Trench; QUEENSLAND INST OF MEDICAL RESEARCH BRISBANE (AUSTRALIA)
|
| The purpose of this project was to identify ovarian cancer susceptibility genes involved in stromal- epithelial cross talk. We have now genotyped 2138 samples for 1536 tagging, ns and miRNA binding site SNPs in 174 genes. Following Quality Control exclusions, the final dataset comprised 1839 samples (675 cases and 1164 controls) with genotype information for 1292 SNPs in 174 genes. We also genotyped 22 SNPs in 2985 cases and 2932 ... |
|
| Mechanisms and Chemoprevention of Ovarian Carcinogenesis |
Feb-2009 |
38 pages |
| Authors:
Dusica Cvetkovic; FOX CHASE CANCER CENTER PHILADELPHIA PA
|
| Ovarian cancer is the most fatal gynecological malignancy. The understanding of the early molecular events leading to ovarian cancer is important for the development of strategies for early detection and prevention. We have demonstrated that DMBA induced mutagenesis in the rat ovary, combined with gonadotropin hormone-mediated enhanced mitogenesis of the ovarian surface epithelium, produces lesions ranging from preneoplastic, early neoplastic to advanced ovarian tumors, resembling human disease. The goal of ... |
|
| Identification and Characterization of Genomic Amplifications in Ovarian Serous Carcinoma |
Jan-2009 |
148 pages |
| Authors:
Tian-Li Wang; JOHNS HOPKINS UNIV BALTIMORE MD SCHOOL OF MEDICINE
|
| The purpose of this proposed study is to apply genome-wide technologies to analyze ovarian cancer genome and transcriptome. We have accomplished all the proposed tasks as stated in the original grant. They include generating digital karyotyping libraries from ovarian carcinomas and perform transcirptome analysis in each amplicon. This effort leads us to identify at least two novel candidate oncogenes, Rsf1 and Notch3, which were up-regulated in both genomic DNA and ... |
|
| Do Deregulated Cas Proteins Induce Genomic Instability in Early-Stage Ovarian Cancer |
Dec-2008 |
12 pages |
| Authors:
Erica A Golemis; INSTITUTE FOR CANCER RESEARCH PHILADELPHIA PA
|
| Increased genomic instability arising from centrosomal amplification has been proposed to be an important factor causing development of traits associated with highly malignant ovarian tumors, including multidrug resistance and increased tendency to metastasis. This proposal addresses the hypothesized interaction between the Cas proteins (HEF1 and p130Cas), Aurora A (AurA) and Ajuba as being likely to contribute to genomic instability and metastatic properties of ovarian tumors. Our work during the no ... |
|
| A Novel Approach to Identify Genes that Modulate Response of Human Ovarian Cancer Cells to Chemotherapeutic Agents Using High-Throughput RNA Interference |
Dec-2008 |
11 pages |
| Authors:
David Azorsa; TRANSLATIONAL GENOMICS RESEARCH INST PHOENIX AZ
|
| The application of HT-RNAi represents an innovative functional genomic strategy to rapidly identify important genes involved in the response of cancer cells to the chemotherapeutic agents. We developed a novel HT-RNAi screening assay using a kinase siRNA library to identify genes that modulate the response of ovarian cancer cells to cisplatin and paclitaxel. HT-RNAi assays were conducted using the cell line SKOV-3 to identify genes that sensitize cells to low ... |
|
| Epigenetic Characterization of Ovarian Cancer |
Dec-2008 |
105 pages |
| Authors:
Susan K Murphy; DUKE UNIV MEDICAL CENTER DURHAM NC
|
| The overall objective of this research was to identify genes that are aberrantly methylated in epithelial ovarian cancer. Our approach was to treat or mock treat primary normal or tumor cultured cells with drugs that inhibit DNA methyltransferase activity and then perform microarray analysis to identify genes that are likely to exhibit methylation-mediated silencing. We also employed similar analysis of 43 ovarian cell lines. Two major criteria identified genes likely ... |
|
| Do Deregulated Cas Proteins Induce Genomic Instability in Early-Stage Ovarian Cancer |
Dec-2008 |
12 pages |
| Authors:
Erica A Golemis; INSTITUTE FOR CANCER RESEARCH PHILADELPHIA PA
|
| Increased genomic instability arising from centrosomal amplification has been proposed to be an important factor causing development of traits associated with highly malignant ovarian tumors, including multidrug resistance and increased tendency to metastasis. This proposal addresses the hypothesized interaction between the Cas proteins (HEF1 and p130Cas), Aurora A (AurA) and Ajuba as being likely to contribute to genomic instability and metastatic properties of ovarian tumors. Our work during the no ... |
|
| A Mouse Model to Investigate Postmenopausal Biology as an Etiology of Ovarian Cancer |
Nov-2008 |
12 pages |
| Authors:
Xiangxi Xu; MIAMI UNIV FL
|
| We are completing this project to use a germ cell deficient Wv mouse model to test the hypothesis of a synergy between oncogenic mutations and postmenopausal biology in ovarian cancer development. We found that crossing of Wv mice into mutant p53 or pten (+/-) background did not lead to a malignant tumor phenotype (Aim 1). Instead, the mutants rescue ovarian germ cells, a very interesting finding. The ovarian surface epithelia ... |
|
| Identification and Characterization of Ovarian Carcinoma Peptide Epitopes Recognized by Cylotoxic T Lymphocytes |
Nov-2008 |
75 pages |
| Authors:
Kevin T Hogan; VIRGINIA UNIV CHARLOTTESVILLE
|
| The purpose of the research was to identify new ovarian cancer tumor antigens that could be used in the development of an ovarian cancer vaccine. The scope of the work involved identifying peptide antigens recognized by ovarian cancer reactive cytotoxic T lymphocytes (CTL). Eleven ovarian cancer cell lines were characterized for their expression of tumor antigens and MHC molecules This was significant because it provided a resource that could be ... |
|
| COX-1 Suppression and Follicle Depletion in the Etiology of Menopause-Associated Ovarian Cancer |
Oct-2008 |
12 pages |
| Authors:
Martin G Belinsky; FOX CHASE CANCER CENTER PHILADELPHIA PA
|
| Menopause is defined as a permanent cessation of menstruation resulting from depletion of germs cells and loss of ovarian follicular activity. Menopausal ovaries undergo morphological changes that are likely related to the increased incidence of ovarian cancer in the peri- and post-menopausal periods. The germ cell-deficient Wv mice recapitulate these post-menopausal alterations in ovarian morphology and develop tubular adenomas. Genetic deletion of cyclooxygenase 1 (COX-1) delays germ cell depletion and ... |
|
| Regulatory T Cells and Host Anti-CML Responses |
01-Jun-2008 |
9 pages |
| Authors:
Wong; K K Jr; CITY OF HOPE NATIONAL MEDICAL CENTER DUARTE CA
|
| CD4+CD25+FoxP-3+ regulatory T-cells (Tregs) suppress immune responses to "self" antigens, but also have been shown to suppress host anti-tumor responses in several human malignancies, including breast, gastrointestinal, and ovarian cancer. Identification of CML Tregs as suppressors of host anti-CML responses could have a significant impact upon CML treatment strategies. Methods are currently available to selectively suppress Tregs, and subsequently boost host anti-CML responses. We have examined the CD4+CD25+FoxP-3+ regulatory T-cell ... |
|
| Modifiers of the Efficacy of Risk-Reducing Salpingo-Oophorectomy for the Prevention of Breast and Ovarian Cancer in Carriers of BRCA1 and BRCA2 Mutations |
May-2008 |
19 pages |
| Authors:
Noah D Kauff; SLOAN-KETTERING INST FOR CANCER RESEARCH NEW YORK
|
| The principle investigator was funded via a Physician-Scientist Training Award to participate in a comprehensive training plan to foster the transition to independent clinical breast cancer researcher. This plan included: 1) conduct of a prospective study examining modifiers of the efficacy of risk-reducing salpingo-oophorectomy (RRSO) for the prevention of breast and ovarian cancer in carriers of BRCA mutations; and 2) participation in a structured training program in research methodology, biostatistics, ... |
|
| Modulators of Response to Tumor Necrosis-Related Apoptosis-Inducing Ligand (TRAIL) Therapy in Ovarian Cancer |
30-Apr-2008 |
9 pages |
| Authors:
Kian Behbakht; COLORADO UNIV HEALTH SCIENCES CENTER AURORA CO
|
| Ovarian cancer is the leading cause of death from gynecologic cancers in the developed world. Most ovarian cancers are diagnosed late and current treatment results only in a 20% 5-year survival in advanced disease. More effective therapies are urgently needed. One of the most promising therapies in development for ovarian cancer is the use of either the Tumor Necrosis Factor-related Apoptosis Inducing Ligand (TRAIL) or agonistic antibodies that activate the ... |
|
| Development of a Multifaceted Ovarian Cancer Therapeutic and Imaging Agent |
01-Apr-2008 |
11 pages |
| Authors:
Francis S Markland; UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES
|
| Ovarian cancer (OC) is the deadliest of all gynecological cancers, with five year survival rates of <45%. One critical feature of the disease is that two thirds of the women diagnosed have advanced disease, and the five year survival rate of this group is <30%. This project outlines the development of a recombinant version of a member of a class of proteins known as disintegrins as an innovative imaging and ... |
|
| Cox-1 Suppression and Follicle Depletion in the Etiology of Menopause- Associated Ovarian Cancer |
Apr-2008 |
12 pages |
| Authors:
Marin G Belinsky; FOX CHASE CANCER CENTER PHILADELPHIA PA
|
| Menopause is defined as a permanent cessation of menstruation resulting from depletion of germs cells and loss of ovarian follicular activity. Menopausal ovaries undergo morphological changes that are likely related to the increased incidence of ovarian cancer in the peri- and post-menopausal periods. The germ cell-deficient Wv mice recapitulate these post-menopausal alterations in ovarian morphology and develop tubular adenomas. Genetic deletion of cyclooxygenase 1 (COX-1) delays germ cell depletion and ... |
|
| Role of PELP1 in EGFR-ER Signaling Crosstalk in Ovarian Cancer Cells |
Apr-2008 |
71 pages |
| Authors:
Ratna K Vadlamudl; TEXAS UNIV HEALTH SCIENCE CENTER AT SAN ANTONIO
|
| Emerging evidence suggests that nuclear receptor (NR) coregulators have potential to act as master genes and their deregulation can promote oncogenesis. Proline-, glutamic acid-, and leucine-rich protein-1 (PELP1/MNAR) is a novel NR coregulator. IHC studies using human ovarian cancer tissue arrays (n=123) showed that PELP1/MNAR is 2 to 3 fold over expressed in 60% of ovarian tumors To examine the significance of PELP1/MNAR in ovarian cancer progression, we have generated ... |
|
| Molecular Imaging of Ovarian Carcinoma Angiogenesis |
Mar-2008 |
16 pages |
| Authors:
Xiaoyuan Chen; STANFORD UNIV CA
|
| This purpose of this proposal is to use high resolution microPET technology to image ovarian cancer integrin expression in vivo. Ovarian cancer is angiogenesis dependent. Integrin av Beta 3, a key player in tumor angiogenesis and metastasis, has been identified as a target for diagnostic and therapeutic interventions for several highly proliferative and metastatic tumor types. Specific Aim 1: To develop and optimize 18F-labeled RGD peptides for ovarian carcinoma targeting. ... |
|
| Levels of Distress in Women at Risk for Ovarian Cancer |
01-Jan-2008 |
24 pages |
| Authors:
Kathryn M Kash; THOMAS JEFFERSON UNIV PHILADELPHIA PA
|
| The overall goal of this study was to determine the levels of distress in women with a family history of ovarian cancer and to identify the mediating factors between risk of developing ovarian cancer and distress. One hundred and eleven women completed a mailed questionnaire about their subjective risk status, their knowledge of ovarian cancer and risk factors, uncertainty about ovarian cancer, levels of anxiety and depression, personality traits, and ... |
|
| PARK2, a Large Common Fragile Site Gene, is Part of a Stress Response Network in Normal Cells that is Disrupted During the Development of Ovarian Cancer |
01-Jan-2008 |
18 pages |
| Authors:
Yu Zhu; David I Smith; MAYO CLINIC ROCHESTER MN
|
| PARK2 (Parkin) is a common fragile site (CFS) gene. We examined Parkin in primary ovarian tumors and found that this gene was frequently inactivated. We also found that re-introduction of Parkin is associated with greater sensitivity to apoptotic induction in ovarian cancer cell lines. We also discovered an entire family of very large common fragile site genes. We measured the expression of Parkin and 13 other CFS genes in panels ... |
|
| Do Deregulated Cas Proteins Induce Genomic Instability In Early Stage Ovarian Cancer? |
01-Dec-2007 |
60 pages |
| Authors:
Erica Golemis; INSTITUTE FOR CANCER RESEARCH PHILADELPHIA PA
|
| Increased genomic instability arising from centrosomal amplification has been proposed to be an important factor causing development of traits associated with highly malignant ovarian tumors, including multidrug resistance and increased tendency to metastasis. This proposal addresses the hypothesized interaction between the Cas proteins (HEF1 and p130Cas), Aurora A (AurA) and Ajuba as being likely to contribute to genomic instability and metastatic properties of ovarian tumors. Our work in the second ... |
|
| Application of Nanotechnology in the Targeted Release of Anticancer Drugs in Ovarian Cancer Treatment |
01-Dec-2007 |
12 pages |
| Authors:
Colleen Feltmate; BRIGHAM AND WOMEN'S HOSPITAL BOSTON MA
|
| Initial study was performed which was localized MagNaGel nanoparticles in an orthotopic ovarian cancer mouse model by MRI and also via IVIS imaging techniques. Mice were injected intraperitoneally with ovarian cancer cells tagged with luciferase gene. Tumor growth was monitored using both a 4.7T small animal MRI and IVIS Imaging system. Once tumor and ascites developed in the mice, cisplatin-loaded MagNagel particles with 10.0 nm IO core were injected into ... |
|
| Dendritic Cell-Based Genetic Immunotherapy for Ovarian Cancer |
Dec-2007 |
73 pages |
| Authors:
James M Mathis; LOUISIANA STATE UNIV IN SHREVEPORT
|
| Adenovirus (Ad)-mediated transduction of dendritic cells (DCs) is inefficient because of the lack of the primary Ad receptor, CAR. CD40 is a surface marker expressed by DCs that plays a crucial role in their maturation and subsequent stimulation of T cells. DC infection with Ad targeted to the CD40 results in increased gene transfer. Cells transduced with CD40-targeted Ad5-SV40-TAg vector showed increased expression of transgene and expression of co-stimulatory molecules ... |
|
| CYP1B1, Oxidative Stress, and Inflammation in the Etiology of Ovarian Epithelial Cancer Using an Avian Model of Ovarian Carcinoma |
01-Nov-2007 |
120 pages |
| Authors:
Dale B Hales; ILLINOIS UNIV AT CHICAGO
|
| Ovarian cancer is the most lethal of the gynecological malignancies due to its late stage of detection. Research in ovarian cancer has been hampered by a lack of suitable animal models. With the exception of the laying hen, no other animal gets ovarian epithelial cancer analogous to the human disease. The study further validates the hen model of ovarian cancer. The results of the study demonstrate that cancer markers in ... |
|
| Identification and Characterization of Ovarian Carcinoma Peptide Epitopes Recognized by Cytotoxic T Lymphocytes |
01-Nov-2007 |
57 pages |
| Authors:
Kevin T Hogan; VIRGINIA UNIV CHARLOTTESVILLE
|
| The purpose of the research is to identify new ovarian cancer tumor antigens that can be used in the immunotherapeutic treatment of ovarian cancer. The scope of this work involves (1) identifying the peptide antigens recognized by ovarian reactive cytotoxic T lymphocytes (CTL); and (2) identify peptide antigens within the Her-2/neu, folate binding protein (FBP), and TAG proteins that give rise to ovarian reactive CTL. Eleven ovarian cancer cell lines ... |
|
| A Double Selection Approach to Achieve Specific Expression of Toxin Genes for Ovarian Cancer Gene Therapy |
01-Nov-2007 |
351 pages |
| Authors:
Gene Siegal; Minghui Wang; David T Curiel; ALABAMA UNIV IN BIRMINGHAM
|
| Gene therapy is a novel treatment modality which offers great potential for the control of carcinoma of the ovary. The efficacy of such approaches, however, is currently limited due to the inability of available gene delivery vehicles (vectors) to achieve efficient and selective gene transfer to target tumor cells. Proposed herein is a strategy to modify one candidate vector, recombinant adenovirus, such that it embodies the requisite properties of efficacy ... |
|
| Societal Interactions in Ovarian Cancer Metastases: A Quorum Sensing Hypothesis |
01-Nov-2007 |
28 pages |
| Authors:
Carrie Rinker-Schaeffer; CHICAGO UNIV IL
|
| It is unknown what specific biochemical and biological mechanisms control metastasis. We pursued the work proposed in this application because it is our assertion that uncovering the mechanism(s) responsible for regulating metastatic colonization in ovarian requires a fresh look from a new perspective. To this end we formulated and began to test a completely novel hypothesis: That a Quorum Sensing mechanism is involved in metastatic colonization. Quorum Sensing is a ... |
|
| Biological Basis for Chemoprevention of Ovarian Cancer. Addendum |
OCT 2007 |
35 pages |
| Authors:
Andrew Berchuck; DUKE UNIV MEDICAL CENTER DURHAM NC
|
| To better understanding the etiology of ovarian cancer, we have initiated a case-control study that considers genetic susceptibility, epidemiologic factors and somatic alterations. Subjects are interviewed in their homes and 1,100 cases and 1,000 controls have been accrued. Blood and cancer samples have been collected and molecular analyses of genetic polymorphisms have been performed. We have performed an Illumina array experiment with 1,536 haplotype tagging single nucleotide polymorphisms in about ... |
|
| A Treatment Stage Specific Approach to Improving Quality of Life for Women with Ovarian Cancer |
OCT 2007 |
17 pages |
| Authors:
Nancy E. Avis; Brigitte Miller; WAKE FOREST UNIV WINSTON-SALEM NC
|
| Our primary objective was to identify the issues that are of greatest concern to women in each of three treatment stages: newly diagnosed with ovarian cancer, in-treatment, and post-treatment. The CARES-SF and FACT-O questionnaires were administered to participants following diagnosis and prior to chemotherapy (baseline), during chemotherapy, following chemotherapy, and after recurrence. Data for the study was collected through mailed questionnaires and telephone follow-up) from women treated at the Wake ... |
|
| A Controlled Trial of Chemoprevention Using COX-2 Inhibitors in an Avian Model of Spontaneous Ovarian Carcinogesis |
01-Sep-2007 |
43 pages |
| Authors:
Mack N Barnes; ALABAMA UNIV IN BIRMINGHAM
|
| The objective of this study was to determine in a controlled chemoprevention trial the ability of a COX-2 inhibitor to inhibit the development of spontaneously arising genital tract adenocarcinoma in the laying hen (Gall us Domesticus) animal model of ovarian cancer. Following a dose finding study for the COX-2 inhibitor Rimadyl 480 hens were utilized in a controlled trial of this agent to determine the subsequent development of genital tract ... |
|
| Improving Quality of Life in Ovarian Cancer Patients: A Brief Intervention for Patients and Their Partners |
SEP 2007 |
18 pages |
| Authors:
Sandra G. Zakowski; ROSALIND FRANKLIN UNIV OF MEDICINE AND SCIENCE CHICAGO IL
|
| The current study examines the effects of a psychological intervention that encourages emotional expression in ovarian cancer patients and their partners. Ovarian cancer patients (n=130) and their partners are randomly assigned to an intervention or a control group. Following Pennebaker's model, subjects in the intervention group are asked to write about their deepest thoughts and feelings regarding their cancer experience for 20 minutes each day for three consecutive days. The ... |
|
| A Fusogenic Oncolytic Herpes Simplex Virus for Therapy of Advanced Ovarian Cancer |
JUN 2007 |
32 pages |
| Authors:
Xiaoliu Zhang; BAYLOR COLL OF MEDICINE HOUSTON TX
|
| The underlying hypothesis for this project is that incorporation of cell membrane fusion function into an oncolytic herpes simplex virus (HSV) can significantly enhance the anti-tumor effect of the virus. Three specific aims have been proposed and they are: 1) to demonstrate that fusogenic oncolytic HSVs are a potent anti-tumor agent for advanced ovarian cancer; 2) to prove that fusogenic oncolytic HSVs have the same safety profile as their non-fusogenic ... |
|
| Modifiers of the Efficacy of Risk-Reducing Salpingo-Oophorectomy for the Prevention of Breast and Ovarian Cancer in Carriers of BRCA1 and BRCA2 |
MAY 2007 |
10 pages |
| Authors:
Noah D. Kauff; SLOAN-KETTERING INST FOR CANCER RESEARCH NEW YORK
|
| The principle investigator was funded via a Physician-Scientist Training Award to participate in a comprehensive training plan to foster the transition to independent clinical breast cancer researcher. This plan included: 1) conduct of a prospective study examining modifiers of the efficacy of risk-reducing salpingo-oophorectomy for the prevention of breast and ovarian cancer in carriers of BRCA mutations; and 2) participation in a structured training program in research methodology biostatistics molecular ... |
|
| Ovarian Cancer Training Program at the Dana Farber/Harvard Cancer Center |
APR 2007 |
7 pages |
| Authors:
Michael Seiden; MASSACHUSETTS GENERAL HOSPITAL BOSTON
|
| This Award funded the initiation of a mentored research experience in ovarian cancer biology at the Dana Farber/Harvard Cancer Center. The primary aims, articulated in the Statement of Work, included creating a mechanism to identify and select outstanding postdoctoral fellows who had a commitment to serious multi-year experience in research that was directly related to a topic in or immediately applicable to ovarian cancer. The second aim was to provide ... |
|
| The Role & Action of Prohibition, an Antiproliferative Gene, in Ovarian Cancer |
APR 2007 |
10 pages |
| Authors:
Winston E. Thompson; MOREHOUSE SCHOOL OF MEDICINE ATLANTA GA
|
| The experiments proposed in this application aim at understanding the mechanisms by which prohibitin induces growth arrest in ovarian cancer. We hypothesize that the prohibitin gene product will substantially induce arrest in ovarian cancer cells and enhance differentiation. Accordingly, we will characterize the expression pattern and function of this gene. In specific aim 1, we will define the spatial, temporal and stage specific cellular expression pattern of prohibitin in normal ... |
|
| The Role of Cyclin E and its Lower Molecular Forms in the Oncogenesis of Ovarian Cancer and its Predictive Value in Patients with Early Stage Ovarian Tumor |
Apr-2007 |
17 pages |
| Authors:
Khandan Keyomarsi; M D ANDERSON CANCER CENTER HOUSTON TX
|
| The deregulation of cell cycle checkpoints, with loss of regulation at the G1/S transition, has been shown to play an important role in the transformation to a malignant phenotype. Our studies have focused on cyclin E, which appears in late G1 and flanks the restriction point .We hypothesize that alterations of cyclin E in ovarian cancer cells contributes to the oncogenesis of ovarian tumors and negatively impacts outcome in patients ... |
|
| Regulation of Leukocyte Infiltration into Ovarian Cancer by Tumor-Stroma Interactions, a Microarray View of Cancer Microenvironment |
MAR 2007 |
59 pages |
| Authors:
Izhak Haviv; Mark Smyth; Carleen Cullinane; Michael Kershaw; Sarah Russell; MELBOURNE UNIV VICTORIA (AUSTRALIA)
|
| Despite compelling cell biological studies and histopathological observations incriminating stromal cells in tumorigenesis, our knowledge of the genes that mediate changes in the tumor microenvironment and interactions among various cell types in epithelial cancer and their role in tumorigenesis is limited. Here, we describe a comprehensive molecular characterization of stromal-epithelial cell interactions, using microarray analysis of co-cultured cell pairs. We further show that these gene expression changes indeed are common ... |
|
| Molecular Imaging of Ovarian Carcinoma Angiogenesis |
MAR 2007 |
69 pages |
| Authors:
Xiaoyuan Chen; STANFORD UNIV CA
|
| This purpose of this proposal is to use high resolution microPET technology to image ovarian cancer integrin expression in vivo. Ovarian cancer is angiogenesis dependent. Integrin , a key player in tumor angiogenesis and metastasis, has been identified as a target for diagnostic and therapeutic interventions for several highly proliferative and metastatic tumor types. The interaction between vitronectin and integrin alphavbeta3 is essential for ovarian cancer cell survival and invasion. ... |
|
| Application of Nanotechnology in the Targeted Release of Anticancer Drugs in Ovarian Cancer Treatment |
01-Dec-2006 |
9 pages |
| Authors:
Colleen Feltmate; BRIGHAM AND WOMEN'S HOSPITAL BOSTON MA
|
| As a pilot study to localize the MagNaGel nanoparticles in an orthotopic ovarian cancer mouse model by MRI, mice were injected intraperitoneally with ovarian cancer cells. Tumor growth was monitored by a 4.7T small animal MRI. Once tumor and ascites developed in the mice, cisplatin-loaded MagNagel particles with 10.0 nm IO core (no targeting ligand) were injected into the tail-vein of the cancer bearing mice. After set time periods, MRI ... |
|
| Mechanism of Ovarian Epithelial Tumor Predisposition in Individuals Carrying Germline BRCA1 Mutations |
DEC 2006 |
56 pages |
| Authors:
Louis Dubeau; UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES
|
| Women with germline mutations in BRCA1 are strongly predisposed to cancers of the ovary and fallopian tubes. Given the strong link between menstrual activity and risk of ovarian cancer in the general population, we hypothesized that BRCA1 might predispose to ovarian cancer indirectly, by influencing ovarian granulosa cells, which play an important role in controlling menstrual cycle progression. We used the Cre-lox system to inactivate the mouse Brca1 gene in ... |
|
| Affinity-Based Serum Proteomics for Ovarian Cancer Early Diagnosis |
DEC 2006 |
12 pages |
| Authors:
Martin W. McIntosh; FRED HUTCHINSON CANCER RESEARCH CENTER SEATTLE WA
|
| Our research project is intended to exploit unique characteristics of phage and yeast recombinant antibodies as the basis for a serum biomarker discovery platform for ovarian cancer. In brief we select from large recombinant libraries those binding sequences which bind to cancer related material but not to control serum then we evaluate these sub libraries in high throughput using novel recombinant antibody arrays probed with serum from our serum repository. ... |
|
Reports by Keyword(s)
*OVARIAN CANCER
